What happened with DCTH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
HEPZATO KIT accounts for most of Delcath Systems’ revenue. It combines the chemotherapy drug melphalan with a delivery system for certain adults whose uveal melanoma, an eye cancer, has spread to the liver and whose liver metastases cannot be surgically removed. The system delivers chemotherapy to the liver and filters blood leaving it before that blood returns to the rest of the body, limiting systemic drug exposure. Each treatment uses a new disposable system.
U.S. hospitals and treatment centers buy HEPZATO directly from Delcath and seek reimbursement for the product and procedure. Centers must complete training under the FDA-required safety program. Delcath may promote HEPZATO only for its approved indication, which includes limits on the extent of liver involvement and disease outside the liver. In Europe, it sells CHEMOSAT directly to hospitals: the delivery device without melphalan. Physicians must obtain and prescribe the drug separately, and Delcath may promote the device only within its approved use.
Sales depend on trained centers treating eligible patients and on public and private insurers providing reimbursement that makes treatment financially workable for providers. Product availability also depends on supplies of critical components and melphalan, including the drug supplied under Delcath’s agreement with Synerx Pharma, LLC and Mylan Teoranta.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Immunocore Holdings plc competes with Delcath’s liver-directed HEPZATO through sales of KIMMTRAK for HLA-A*02:01-positive adults with metastatic uveal melanoma, an overlapping patient group. Watch KIMMTRAK adoption in that group, which Delcath says represents approximately 45% of uveal melanoma patients.
IDEAYA Biosciences, Inc. is developing darovasertib-based treatments that could compete for patients eligible for Delcath’s HEPZATO; it retains U.S. rights and receives payments from Servier for rights outside the United States. Watch its potentially registration-enabling Phase 2/3 trial of darovasertib with crizotinib as first-line treatment for HLA-A2-negative metastatic uveal melanoma—the combination is not yet approved for that disease.
Replimune Group, Inc. could challenge Delcath’s HEPZATO with RP2 plus nivolumab for metastatic uveal melanoma, but it had no approved products or product-sales revenue through March 31, 2026. Watch the randomized Phase 2/3 trial in adults who have not received immune checkpoint inhibitors; RP2 is not yet approved for this disease.
TriSalus Life Sciences, Inc. sells TriNav to U.S. hospitals and ambulatory surgery centers for liver-tumor embolization procedures, offering regional treatment alternatives to Delcath’s delivery of chemotherapy to the liver. TriNav sales are the line to watch: they show demand for a device used in chemoembolization and radioembolization for primary liver cancer and liver metastases.
AngioDynamics, Inc. sells cancer-treatment devices, including ablation systems, that offer liver-directed alternatives to Delcath’s products. Watch developments in its NanoKnife and Solero ablation systems rather than treating its broader cardiovascular-device business as a direct read on competition for Delcath.
Delcath Systems Inc earningsThis company
Delcath Systems Inc relies mainly on U.S. HEPZATO sales for revenue, and this report will show whether use at treatment centers is still translating into sales and better operating results.
Read HEPZATO revenue alongside gross profit and operating results. Rising revenue with improving operating results would show that wider use at treatment centers is increasingly supporting profitability; slower revenue growth or weaker operating results would show commercialization costs still weigh on that path. CHEMOSAT revenue helps show whether growth remains mainly driven by U.S. HEPZATO.
Immunocore Holdings plc earningsIMCR
Immunocore Holdings plc sells KIMMTRAK for some people with metastatic uveal melanoma, and its report can show how strongly that treatment is drawing patients from the group that overlaps with HEPZATO.
Look at Immunocore's disclosures on KIMMTRAK sales and patient use. Growth would indicate stronger traction for this treatment among the overlapping patient group, giving patients more competition to HEPZATO; slower growth would be a weaker sign of competitive pressure, but would not show that patients are turning to HEPZATO.
